证券简称：力生制药 证券代码：002393 渤海证券股份有限公司 关于 天津力生制药股份有限公司 调整 2022 年限制性股票激励计划回购价格 暨回购注销部分激励对象已获授但尚未解除限售的 限制性股票事项 之 独立财务顾问报告 独立财务顾问 签署日期：二〇二五年九月 | | | | 第一章 释义 . | | --- | | 第二章 声明 . | | 第三章 基本假设 . | | 第四章 激励计划履行的相关审批程序 . | | 第五章 本次激励股份回购价格调整的具体情况 | | 第六章 本次回购注销情况 . | | 第七章 独立财务顾问意见 . | | 第八章 备查文件 | 第一章 释义 以下词语如无特殊说明，在本文中具有如下含义： | 力生制药、本公司、公司 | 指 | 天津力生制药股份有限公司 | | --- | --- | --- | | 渤海证券、独立财务顾 问、本独立财务顾问 | 指 | 渤海证券股份有限公司 | | | | 《渤海证券股份有限公司关于天津力生制药股份有限公 | | 独立财务顾问报告 | 指 | 司调整 2022 年限制性股票激励计划回购价格暨回购注销 部分激励对象已获授但尚未解除限售 ...

关于 天津力生制药股份有限公司2025年第二次临时股东会 之 法律意见书 天津市四方君汇律师事务所 Join & High Law Office 关于天津力生制药股份有限公司 2025 年第二次临时股东会之法律意见书 致：天津力生制药股份有限公司 天津四方君汇律师事务所（以下简称"本所"）接受天津力生制药股份有限公司（以下简 称"公司"）委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他规范性文件（以下简称 "法律、法规"）以及《天津力生制药股份有限公司章程》（以下简称"《公司章程》"）有 关规定，就公司召开 2025 年第二次临时股东会（以下简称"本次股东会"）有关事宜出具本 法律意见书。 本法律意见书仅就本次股东会的召集和召开程序、出席本次股东会人员的资格、召集人资 格、会议表决程序是否符合法律、法规及《公司章程》规定，以及表决结果是否合法有效发表 意见，并不对本次股东会所审议的议案内容以及该等议案所表述的相关事实的真实性、准确性 或合法性发表意见。 为出具本法律意见书，本所律师审查了本次股东会相关的文件、资料，并对本次股 ...

2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2025-060 天津力生制药股份有限公司 特别提示： 1.本次股东会未出现否决提案的情形。 2.本次股东会未涉及变更以往股东会已通过的决议。 1．会议召开时间 （1）现场会议：2025年09月08日（星期一）下午2:40开始 （2）网络投票：2025年09月08日（星期一） 其中通过深圳证券交易所交易系统进行网络投票的具体时间为2025年09月08日上午 9:15—9:25,9:30—11:30和13:00—15:00；通过深圳证券交易所互联网投票系统进行网络 投票的具体时间为2025年09月08日9:15～15:00期间的任意时间。 2．会议召开地点：天津力生制药股份有限公司会议室 天津市西青经济技术开发区赛达北一道16号 3．会议方式：本次股东会采取现场投票与网络投票相结合的方式 3.本次股东会采取现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 | 1.总体出席情况 | 196 | 1 ...

2019年-2025年1-7月全国化学原料和化学制品制造业出口货值统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：海南海药（000566），东北制药（000597），亚太实业（000691），通化金马（000766）， 北大医药（000788），力生制药（002393），海普瑞（002399），科伦药业（002422），杭氧股份 （002430），长江健康（002435），誉衡药业（002437），华软科技（002453） 相关报告：智研咨询发布的《2025-2031年中国基础化学原料行业市场供需态势及投资前景研判报告》 根据国家统计局数据可知：2025年7月全国化学原料和化学制品制造业出口货值为496.4亿元，同比增长 2.7%；2025年1-7月全国化学原料和化学制品制造业累计出口货值为3177.1亿元，累计同比下降1.8%。 ...

Summary of Key Points from Conference Call Records Company: Horizon Robotics - **Revenue Performance**: In H1 2025, Horizon Robotics reported revenue of 1.57 billion yuan, a year-on-year increase of 68%, exceeding the expected 1.43 billion yuan. Gross profit was 1.02 billion yuan, a 39% increase year-on-year, but slightly below the expected 1.04 billion yuan [1] - **Business Segmentation**: Revenue from automotive products and solutions reached 780 million yuan, up 250% year-on-year, with shipments of 1.98 million units, a 115% increase. Revenue from automotive licensing and services was 740 million yuan, a 6.9% increase year-on-year [1] - **Market Position**: Horizon Robotics is the first domestic company to achieve a shipment volume of over 10 million units in intelligent driving technology, holding market shares of 32.4% in autonomous driving computing solutions and 45.8% in ADAS front-view integrated machines, both ranking first in the market [1] - **Core Partner**: Zhongke Chuangda, which has a joint venture with Horizon Robotics, reported a non-net profit of 49 million yuan in Q2 2025, a 16-fold increase year-on-year, driven by a 136% increase in revenue from AloT business [1] Industry: Satellite Communication - **Government Initiatives**: On August 27, 2025, the Ministry of Industry and Information Technology released guidelines to promote the development of the satellite communication industry, aiming for over 10 million users of direct satellite connections by 2030 [2] - **Market Developments**: Domestic progress includes China Telecom's plan to promote over 30 direct connection models by May 2025, with annual sales expected to exceed 16 million units [2] - **Key Technologies**: Phased array and beamforming technologies are critical for the implementation of direct satellite communication [3] Industry: Medical and Pharmaceutical - **Policy Framework**: The Ministry of Commerce and Jiangsu Provincial Government issued a development plan for the biopharmaceutical industry on August 27, 2025, focusing on innovation in drugs and high-end medical devices [5] - **Market Size**: In 2024, Jiangsu is expected to approve 352 new drugs, including 13 innovative drugs, leading the nation. The biopharmaceutical cluster in Jiangsu is projected to generate revenue of 454.39 billion yuan in 2024, accounting for 15.3% of the national total [5] - **Core Companies**: Weisi Medical, specializing in non-invasive brain-machine interfaces, and Zhaoyan New Drug, which provides non-clinical research services, are highlighted as key players in the sector [5] Company: Dongtian Microelectronics - **Financial Performance**: In H1 2025, Dongtian Microelectronics reported revenue of 376 million yuan, a 42.29% increase year-on-year, with a non-net profit of approximately 49.78 million yuan, up 109.47% [6] - **Product Expansion**: The company is expanding its product offerings in optical communication and consumer electronics, including camera optical components supplied to Huawei [6] Company: Haosi Automotive Electronics - **Strategic Partnership**: Haosi Automotive Electronics has become a key partner of NVIDIA Jetson Thor, focusing on developing control systems for robotics [7] - **Market Trends**: The value of single-vehicle perception systems is increasing, with prices rising from below 1,000 yuan to 3,000-4,000 yuan per unit due to the proliferation of intelligent driving technologies [7] Company: Yunnan Energy Investment - **Renewable Energy Development**: Yunnan Rongyao New Energy is undergoing compliance checks for its integration into Yunnan Energy Investment, which will increase its renewable energy capacity by nearly 50% [8] - **Financial Projections**: Assuming an annual power generation of 1.2 billion kWh and an electricity price of 0.35 yuan per kWh, the projected annual revenue could reach approximately 420 million yuan, with net profits estimated between 150 million to 200 million yuan [8] Company: Zhongxin Group - **Revenue Growth**: In Q2 2025, Zhongxin Group reported revenue of 1.246 billion yuan, a 161% increase year-on-year, driven by land development and industrial investment [9] - **Operational Metrics**: The company has developed a total area of 3 million square meters in industrial parks, with an occupancy rate of 81% [9] Company: Broadcom Integration - **AI Chip Demand**: Broadcom Integration is benefiting from the growing demand for AI chips in smart terminals, with a focus on Wi-Fi MCU and various AI-integrated chips for applications in AI glasses and toys [10]

Core Viewpoint - The company has received approval for its self-developed potassium chloride sustained-release tablets, which are expected to enhance its product portfolio and market share in the pharmaceutical industry [1][3]. Group 1: Product Approval and Characteristics - The potassium chloride sustained-release tablets have been approved by the National Medical Products Administration, with specifications of 0.5g and 0.6g [1]. - This product is classified as a Category 3 generic drug under new chemical drug registration, which is considered equivalent to passing the consistency evaluation [1]. - The sustained-release technology offers advantages such as improved medication adherence, stable blood drug concentration, reduced peak-trough fluctuations, and minimized side effects [1]. Group 2: Research and Development Achievements - The company has developed unique large-scale production technology for the potassium chloride sustained-release tablets, ensuring stable production and high efficiency [2]. - The research institute has successfully demonstrated bioequivalence between the new product and the original formulation, achieving consistent therapeutic effects [2]. - The company has also secured a patent for the preparation method of the potassium chloride sustained-release tablets, marking a breakthrough in core technology [2]. Group 3: Market Potential - The potassium chloride sustained-release tablets are included in the 2024 National Medical Insurance Directory, indicating significant market potential [2]. - Sales figures for the potassium chloride sustained-release tablets are projected to grow from 350 million yuan in 2022 to 400 million yuan in 2024 [2]. Group 4: Strategic Direction - The potassium chloride sustained-release tablets represent an upgrade to the company's existing product line, aimed at capturing a larger market share and generating greater benefits [3]. - The company plans to continue enhancing research and industrial collaboration to provide accessible quality medications for patients while creating long-term value for investors [3].

Group 1 - The core viewpoint of the article highlights the growth in the number of enterprises in the chemical raw materials and chemical products manufacturing industry, which increased by 1,021 to a total of 26,860 enterprises in the first half of 2025, representing a year-on-year growth of 3.95% [1] - The proportion of chemical raw materials and chemical products manufacturing enterprises in the total industrial enterprises is 5.16% [1] - The report referenced is the "2025-2031 China Basic Chemical Raw Materials Industry Market Supply and Demand Situation and Investment Prospects Analysis Report" published by Zhiyan Consulting [1] Group 2 - The data indicates that the threshold for scale industrial enterprises has been raised from an annual main business income of 5 million yuan to 20 million yuan since 2011 [1] - Zhiyan Consulting is recognized as a leading industry consulting agency in China, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1] - The consulting firm emphasizes its commitment to delivering quality services and market insights to empower investment decisions [1]

Group 1 - On August 26, a total of 3,713 stocks in the A-share market received financing funds for purchase, with 645 stocks having purchase amounts exceeding 100 million [1] - The top three stocks by financing purchase amount were Dongfang Caifu, Shenghong Technology, and Zhongke Shuguang, with amounts of 2.877 billion, 2.852 billion, and 2.803 billion respectively [1] - Seven stocks had financing purchase amounts accounting for over 30% of the total transaction amount on that day, with Jingpin Special Equipment, Lisheng Pharmaceutical, and Wanyi Technology ranking highest at 46.34%, 37.34%, and 35.63% respectively [1] Group 2 - There were 53 stocks that received a net financing purchase exceeding 100 million, with Shenghong Technology, Hanwujishi-U, and Zhongke Shuguang leading in net purchase amounts of 1.042 billion, 593 million, and 543 million respectively [1]

Core Viewpoint - The company, Lisheng Pharmaceutical, has received drug registration certificates from the National Medical Products Administration for its potassium chloride sustained-release tablets in two specifications: 0.5g and 0.6g [1]. Group 1 - The company announced the receipt of the drug registration certificate for potassium chloride sustained-release tablets 0.5g (Batch No: 2025S02514) [1] - The company also received the drug registration certificate for potassium chloride sustained-release tablets 0.6g (Batch No: 2025S02515) [1] - Both products have successfully passed the drug marketing license application [1]

Overview - Tianjin Lisheng Pharmaceutical Co., Ltd. has received drug registration certificates for potassium chloride sustained-release tablets in 0.5g and 0.6g specifications from the National Medical Products Administration [1][2] Drug Information - The potassium chloride sustained-release tablets are classified as chemical drugs and are intended for the treatment and prevention of hypokalemia associated or not associated with metabolic alkalosis [1] - The drug registration numbers are 2025S02514 for 0.5g and 2025S02515 for 0.6g [1] Impact on the Company - The approval of this drug will enhance the company's product line for treating digestive system diseases and improve its market competitiveness [2] - The potassium chloride sustained-release tablets are approved under Category 3 of chemical drugs, which is beneficial for expanding market sales and positively impacting future operating performance [2]